SHR6390
Drug timelines are a Plus or Pro feature.
15 regulatory and trial events tracked for SHR6390, covering 2016-04-12 to 2024-12-17. Get the full timeline:
Most recent: Clinical Trial Update: Famitinib Plus SHR6390 and Endocrine Therapy in the Treatment of HR-positive, HER2-negative Advanced Breast Cancer [Phase 1, Phase 2]